Fig. 3: Pathway-treatment interaction analysis across cancer types. | Nature Communications

Fig. 3: Pathway-treatment interaction analysis across cancer types.

From: Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers

Fig. 3: Pathway-treatment interaction analysis across cancer types.

Pathway–treatment interactions are shown for (a) lung and upper tract cancers, b breast and ovarian cancers, c skin cancers, (d). gastrointestinal cancers, e. genitourinary cancers. For each cancer type and first-line treatment, pathways with significant interactions with that treatment are listed (two-sided Wald test P value < 0.05 and overall FDR  < 0.05). The font size of a pathway indicates the fraction of patients in that treatment group with any gene mutation in that pathway. The color indicates the interaction hazard ratio (HR) of the pathway. Red (blue) indicates that mutations in the pathway have negative (positive) interactions and impact the survival of patients receiving a particular treatment.

Back to article page